Please login to the form below

Not currently logged in
Email:
Password:

FDA issues haloperidol cardiovascular prescribing update

The FDA has updated the warnings section of the prescribing information for J&J's Haldol treatment for psychosis

The FDA has updated the warnings section of the prescribing information for Johnson & Johnson's (J&J) Haldol (haloperidol) treatment for psychosis.

The label has been revised to include a new cardiovascular subsection regarding cases of sudden death, QT prolongation and Torsades de Pointes (TdP) in patients treated with haloperidol, especially when given intravenously, or at doses higher than recommended. Both cases refer to different types of ventricular tachycardia, where heart beat speed increases.

Although injectable haloperidol is only approved by the FDA for intramuscular injection, there is strong evidence that the intravenous administration of haloperidol is a relatively common off-label clinical practice.

There have been at least 28 case reports of QT prolongation and TdP, some with fatal outcome in the context of off-label intravenous haloperidol. Healthcare professionals should consider this new risk information when making individual treatment decisions for their patients.

According to Reuters, J&J's stock fell USD 0.26 to rest at USD 62.94 in 17 September afternoon trading on the New York Stock Exchange composite.

Atypical antipsychotics have replaced Haldol and posted sales of USD 11.5bn in 2006, according to IMS Health data. J&J does not routinely release Haldol sales figures.

18th September 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...
Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...